BPTH Share Price | Bio-Path Holdings, Inc. Stock Analysis & Recommendation

Q: What does Bio-Path Holdings, Inc. do?

Overview:Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company in the Pharmaceuticals & Biotechnology industry with a market cap of USD 1.66 Million.Financial Snapshot:Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)Market-cap: USD 1.66 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.07Return on Equity: 436.93%Price to Book: -0.64Contact Details:Address: 4710 Bellaire Blvd Ste 210, BELLAIRE TX : 77401-4505Tel: ['1 832 7421357', '1 832 7421369']Website: http://www.biopathholdings.com/

Q: Is Bio-Path Holdings, Inc. overvalued or undervalued?

As of 15 October 2023, Bio-Path Holdings, Inc. has moved from fair to attractive. The company is currently undervalued. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3. When compared to peers, such as Moderna with a P/E ratio of 15.0 and Gilead Sciences at 10.0, Bio-Path appears to have a more favorable valuation.Additionally, Bio-Path's recent stock performance has outpaced the Sensex, reinforcing the notion that the market may not fully recognize its potential. Overall, the combination of strong financial ratios and favorable peer comparisons supports the conclusion that Bio-Path Holdings, Inc. is undervalued.

Q: Is Bio-Path Holdings, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Bio-Path Holdings, Inc. has changed from mildly bearish to bearish. The overall stance is bearish with weak strength indicated by the daily moving averages being bearish and the KST showing bearish signals on both weekly and monthly time frames. The Bollinger Bands also reflect a bearish sentiment on the monthly scale. The MACD is mildly bullish on both weekly and monthly time frames, but this is overshadowed by the bearish indicators. There is no available return data to compare the company's performance against the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.87 k

Shareholding (Sep 2025)

FII

0.50%

Held by 6 FIIs

DII

99.17%

Held by 0 DIIs

Promoter

0.00%

What does Bio-Path Holdings, Inc. do?

22-Jun-2025

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology-focused company specializing in antisense drug development, with a market cap of USD 1.66 million and a recent net profit of -3 million. The company has no dividend yield and is currently loss-making.

View full answer

Who are in the management team of Bio-Path Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Bio-Path Holdings, Inc. includes Peter Nielsen (Chairman, CEO, Co-Founder, CFO), Douglas Morris (Director, Secretary), and independent directors Paul Aubert, Heath Cleaver, and Martina Molsbergen. They oversee the company's strategic direction and operations.

View full answer

Is Bio-Path Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Bio-Path Holdings, Inc. is considered undervalued with a favorable P/E ratio of 12.5 compared to peers, strong financial ratios, and recent stock performance that has outpaced the market.

View full answer

Is Bio-Path Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Bio-Path Holdings, Inc. shows a bearish trend with weak strength, indicated by bearish daily moving averages and KST signals, despite a mildly bullish MACD on weekly and monthly time frames.

View full answer

Compare Bio-Path Holdings, Inc. with Similar Stocks

Revelation Biosciences, Inc.Bon Natural Life Ltd.PaxMedica, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.06

Return on Equity

141.33%

Price to Book

-0.06

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-64.29%

6 Months

-91.89%

1 Year

-97.4%

2 Years

-99.81%

3 Years

-99.92%

4 Years

-99.96%

5 Years

-99.95%

Bio-Path Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-6.80%

EBIT to Interest (avg)

-12.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.07

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

5.06%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.61

EV to EBIT

-0.15

EV to EBITDA

-0.16

EV to Capital Employed

-0.74

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.33%)

Foreign Institutions

Held by 6 Foreign Institutions (0.5%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 52.38% vs 34.38% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.50",
          "val2": "-2.60",
          "chgp": "80.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.40",
          "val2": "0.50",
          "chgp": "-180.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-2.10",
          "chgp": "52.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 38.51% vs -15.83% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.80",
          "val2": "-15.70",
          "chgp": "24.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.10",
          "val2": "-0.30",
          "chgp": "800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.90",
          "val2": "-16.10",
          "chgp": "38.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.50

-2.60

80.77%

Interest

0.10

0.00

Exceptional Items

-0.40

0.50

-180.00%

Consolidate Net Profit

-1.00

-2.10

52.38%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 52.38% vs 34.38% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.80

-15.70

24.84%

Interest

0.00

Exceptional Items

2.10

-0.30

800.00%

Consolidate Net Profit

-9.90

-16.10

38.51%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 38.51% vs -15.83% in Dec 2023

All Annual Results

Company CV

About Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc.

Pharmaceuticals & Biotechnology

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.

Company Coordinates

Company Details

4710 Bellaire Blvd Ste 210 , BELLAIRE TX : 77401-4505

Tel: 1 832 74213571 832 7421369

http://www.biopathholdings.com/

Registrar Details

Bio-Path Holdings, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does Bio-Path Holdings, Inc. do?

Watch in Real-Time

Who are in the management team of Bio-Path Holdings, Inc.?

Is Bio-Path Holdings, Inc. overvalued or undervalued?

Is Bio-Path Holdings, Inc. technically bullish or bearish?

Compare Bio-Path Holdings, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Bio-Path Holdings, Inc.

Company Coordinates